Primary lymphoma of the lacrimal sac: an EORTC ophthalmic oncology task force study
Aim: To define the clinical and histopathological characteristics of primary lacrimal sac lymphoma in a predominantly white population. Methods: Specimens of lacrimal sac lymphoma and follow up data were solicited from members of the Ophthalmic Oncology Task Force of the European Organization for Re...
Gespeichert in:
| Veröffentlicht in: | British journal of ophthalmology 2006-08, Vol.90 (8), p.1004-1009 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1009 |
|---|---|
| container_issue | 8 |
| container_start_page | 1004 |
| container_title | British journal of ophthalmology |
| container_volume | 90 |
| creator | Sjö, L D Ralfkiaer, E Juhl, B R Prause, J U Kivelä, T Auw-Haedrich, C Bacin, F Carrera, M Coupland, S E Delbosc, B Ducrey, N Kantelip, B Kemeny, J L Meyer, P Sjö, N C Heegaard, S |
| description | Aim: To define the clinical and histopathological characteristics of primary lacrimal sac lymphoma in a predominantly white population. Methods: Specimens of lacrimal sac lymphoma and follow up data were solicited from members of the Ophthalmic Oncology Task Force of the European Organization for Research and Treatment of Cancer (EORTC) and the European Ophthalmic Pathology Society (EOPS). Specimens were stained with haematoxylin and eosin and an immunohistochemical panel against leucocyte antigens was applied. Diagnosis was reached by consensus of five experienced pathologists according to the World Health Organization classification system. The histopathological findings were correlated with the clinical data. Results: Of 15 primary lacrimal sac lymphomas, five (33%) were diffuse large B cell lymphoma (DLBCL), five (33%) were extranodal marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma), three were classified as “transitional MALT lymphoma,” being in transition from MALT lymphoma to DLBCL, and two were unclassified B cell lymphomas. Nine of the patients were female, and the median age at the time of diagnosis was 71 years (range 45–95 years). The most frequent presenting symptoms were epiphora (85%), swelling in the region of the lacrimal sac (79%), and dacryocystitis (21%). All but one patient presented in stage I. Systemic spread occurred in three of nine patients (33%). The 5 year overall survival was 65%. Conclusions: DLBCL and MALT lymphoma are equally common in the lacrimal sac in contrast with the remaining periorbital and/or orbital region where MALT lymphoma predominates. |
| doi_str_mv | 10.1136/bjo.2006.090589 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1857190</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4012418311</sourcerecordid><originalsourceid>FETCH-LOGICAL-b590t-dbcd39ef6c8a40fb9bd8a4d61614739fe041dd5b2942f549529d7912272e9d903</originalsourceid><addsrcrecordid>eNqFksFv0zAUxi0EYt3gzA1ZQnCYSGc7jh3vgDRVG0Mq2wSjBy6WYztLOicudjrR_x6XVBvsspNtvd9773vPHwBvMJpinLOjaumnBCE2RQIVpXgGJpiyMiOIi-dgghDiGcYM74H9GJfpSRjmL8EeZoyTnIgJ-H4V2k6FDXSbbtX4TkFfw6Gx0Cm9jTgYlT6Gqoenl9-uZ9CvmqFRrms19L32zt9s4KDiLax90BbGYW02r8CLWrloX-_OA_Dj7PR6dp7NLz9_mZ3Ms6oQaMhMpU0ubM10qSiqK1GZdDEs6aU8F7VFFBtTVERQUhdUFEQYLjAhnFhhBMoPwKex7mpdddZo2w9BObkaJ5JetfL_SN828sbfSVwWHP8t8HEs0DxKOz-Zy7aPNnQSoSSGUnqHE_5h1y_4X2sbB9m1UVvnVG_9OkpWsiLpzJ8EsRBp_6xM4LtH4NKvQ5-WJjHnpSCUFCxRRyOlg48x2PpeK0ZyawOZbCC3NpCjDVLG238388Dv_j0B73eAilq5Oqhet_GB44Khkm5HzkaujYP9fR9X4VYynvNCXixmkizmF4uvP6_kWeIPR77qlk-q_ANfu9ZY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1778924256</pqid></control><display><type>article</type><title>Primary lymphoma of the lacrimal sac: an EORTC ophthalmic oncology task force study</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Sjö, L D ; Ralfkiaer, E ; Juhl, B R ; Prause, J U ; Kivelä, T ; Auw-Haedrich, C ; Bacin, F ; Carrera, M ; Coupland, S E ; Delbosc, B ; Ducrey, N ; Kantelip, B ; Kemeny, J L ; Meyer, P ; Sjö, N C ; Heegaard, S</creator><creatorcontrib>Sjö, L D ; Ralfkiaer, E ; Juhl, B R ; Prause, J U ; Kivelä, T ; Auw-Haedrich, C ; Bacin, F ; Carrera, M ; Coupland, S E ; Delbosc, B ; Ducrey, N ; Kantelip, B ; Kemeny, J L ; Meyer, P ; Sjö, N C ; Heegaard, S ; European Organization for Research and Treatment of Cancer</creatorcontrib><description>Aim: To define the clinical and histopathological characteristics of primary lacrimal sac lymphoma in a predominantly white population. Methods: Specimens of lacrimal sac lymphoma and follow up data were solicited from members of the Ophthalmic Oncology Task Force of the European Organization for Research and Treatment of Cancer (EORTC) and the European Ophthalmic Pathology Society (EOPS). Specimens were stained with haematoxylin and eosin and an immunohistochemical panel against leucocyte antigens was applied. Diagnosis was reached by consensus of five experienced pathologists according to the World Health Organization classification system. The histopathological findings were correlated with the clinical data. Results: Of 15 primary lacrimal sac lymphomas, five (33%) were diffuse large B cell lymphoma (DLBCL), five (33%) were extranodal marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma), three were classified as “transitional MALT lymphoma,” being in transition from MALT lymphoma to DLBCL, and two were unclassified B cell lymphomas. Nine of the patients were female, and the median age at the time of diagnosis was 71 years (range 45–95 years). The most frequent presenting symptoms were epiphora (85%), swelling in the region of the lacrimal sac (79%), and dacryocystitis (21%). All but one patient presented in stage I. Systemic spread occurred in three of nine patients (33%). The 5 year overall survival was 65%. Conclusions: DLBCL and MALT lymphoma are equally common in the lacrimal sac in contrast with the remaining periorbital and/or orbital region where MALT lymphoma predominates.</description><identifier>ISSN: 0007-1161</identifier><identifier>EISSN: 1468-2079</identifier><identifier>DOI: 10.1136/bjo.2006.090589</identifier><identifier>PMID: 16672329</identifier><identifier>CODEN: BJOPAL</identifier><language>eng</language><publisher>BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd</publisher><subject>Age ; Aged ; Aged, 80 and over ; Antigens, CD ; Antigens, CD - metabolism ; Antigens, Neoplasm ; Antigens, Neoplasm - metabolism ; Biological and medical sciences ; Chemotherapy ; CHOP ; Classification ; Clinical Science - Extended Report ; complete remission ; cyclophosphamide + hydroxydoxorubicine + oncovine + prednisone ; diffuse large B cell lymphoma ; DLBCL ; EOPS ; EORTC ; European Ophthalmic Pathology Society ; European Organization for Research and Treatment of Cancer ; Female ; Hematologic and hematopoietic diseases ; Humans ; Immunology ; Lacrimal Apparatus Diseases ; Lacrimal Apparatus Diseases - diagnosis ; Lacrimal Apparatus Diseases - pathology ; Lacrimal Apparatus Diseases - therapy ; lacrimal sac ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Life Sciences ; Lymphoma ; Lymphoma, B-Cell ; Lymphoma, B-Cell - diagnosis ; Lymphoma, B-Cell - pathology ; Lymphoma, B-Cell - therapy ; Lymphoma, B-Cell, Marginal Zone ; Lymphoma, B-Cell, Marginal Zone - diagnosis ; Lymphoma, B-Cell, Marginal Zone - pathology ; Lymphoma, B-Cell, Marginal Zone - therapy ; Lymphoma, Large B-Cell, Diffuse ; Lymphoma, Large B-Cell, Diffuse - diagnosis ; Lymphoma, Large B-Cell, Diffuse - pathology ; Lymphoma, Large B-Cell, Diffuse - therapy ; Male ; MALT ; MALT lymphoma ; Medical prognosis ; Medical sciences ; Middle Aged ; Miscellaneous ; mucosa associated lymphoid tissue ; ocular lymphoma ; Ophthalmology ; Patients ; Radiation therapy ; REAL ; Retrospective Studies ; Revised European-American Classification of Lymphoid Neoplasms ; Studies ; Surgery ; Task forces ; Tumors</subject><ispartof>British journal of ophthalmology, 2006-08, Vol.90 (8), p.1004-1009</ispartof><rights>Copyright 2006 British Journal of Ophthalmology</rights><rights>2006 INIST-CNRS</rights><rights>Copyright: 2006 Copyright 2006 British Journal of Ophthalmology</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>Copyright © 2006 BMJ Publishing Group</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b590t-dbcd39ef6c8a40fb9bd8a4d61614739fe041dd5b2942f549529d7912272e9d903</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://bjo.bmj.com/content/90/8/1004.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://bjo.bmj.com/content/90/8/1004.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,230,314,723,776,780,881,3183,23550,27901,27902,53766,53768,77343,77374</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17960841$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16672329$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://inserm.hal.science/inserm-00473444$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Sjö, L D</creatorcontrib><creatorcontrib>Ralfkiaer, E</creatorcontrib><creatorcontrib>Juhl, B R</creatorcontrib><creatorcontrib>Prause, J U</creatorcontrib><creatorcontrib>Kivelä, T</creatorcontrib><creatorcontrib>Auw-Haedrich, C</creatorcontrib><creatorcontrib>Bacin, F</creatorcontrib><creatorcontrib>Carrera, M</creatorcontrib><creatorcontrib>Coupland, S E</creatorcontrib><creatorcontrib>Delbosc, B</creatorcontrib><creatorcontrib>Ducrey, N</creatorcontrib><creatorcontrib>Kantelip, B</creatorcontrib><creatorcontrib>Kemeny, J L</creatorcontrib><creatorcontrib>Meyer, P</creatorcontrib><creatorcontrib>Sjö, N C</creatorcontrib><creatorcontrib>Heegaard, S</creatorcontrib><creatorcontrib>European Organization for Research and Treatment of Cancer</creatorcontrib><title>Primary lymphoma of the lacrimal sac: an EORTC ophthalmic oncology task force study</title><title>British journal of ophthalmology</title><addtitle>Br J Ophthalmol</addtitle><description>Aim: To define the clinical and histopathological characteristics of primary lacrimal sac lymphoma in a predominantly white population. Methods: Specimens of lacrimal sac lymphoma and follow up data were solicited from members of the Ophthalmic Oncology Task Force of the European Organization for Research and Treatment of Cancer (EORTC) and the European Ophthalmic Pathology Society (EOPS). Specimens were stained with haematoxylin and eosin and an immunohistochemical panel against leucocyte antigens was applied. Diagnosis was reached by consensus of five experienced pathologists according to the World Health Organization classification system. The histopathological findings were correlated with the clinical data. Results: Of 15 primary lacrimal sac lymphomas, five (33%) were diffuse large B cell lymphoma (DLBCL), five (33%) were extranodal marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma), three were classified as “transitional MALT lymphoma,” being in transition from MALT lymphoma to DLBCL, and two were unclassified B cell lymphomas. Nine of the patients were female, and the median age at the time of diagnosis was 71 years (range 45–95 years). The most frequent presenting symptoms were epiphora (85%), swelling in the region of the lacrimal sac (79%), and dacryocystitis (21%). All but one patient presented in stage I. Systemic spread occurred in three of nine patients (33%). The 5 year overall survival was 65%. Conclusions: DLBCL and MALT lymphoma are equally common in the lacrimal sac in contrast with the remaining periorbital and/or orbital region where MALT lymphoma predominates.</description><subject>Age</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antigens, CD</subject><subject>Antigens, CD - metabolism</subject><subject>Antigens, Neoplasm</subject><subject>Antigens, Neoplasm - metabolism</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>CHOP</subject><subject>Classification</subject><subject>Clinical Science - Extended Report</subject><subject>complete remission</subject><subject>cyclophosphamide + hydroxydoxorubicine + oncovine + prednisone</subject><subject>diffuse large B cell lymphoma</subject><subject>DLBCL</subject><subject>EOPS</subject><subject>EORTC</subject><subject>European Ophthalmic Pathology Society</subject><subject>European Organization for Research and Treatment of Cancer</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Immunology</subject><subject>Lacrimal Apparatus Diseases</subject><subject>Lacrimal Apparatus Diseases - diagnosis</subject><subject>Lacrimal Apparatus Diseases - pathology</subject><subject>Lacrimal Apparatus Diseases - therapy</subject><subject>lacrimal sac</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Life Sciences</subject><subject>Lymphoma</subject><subject>Lymphoma, B-Cell</subject><subject>Lymphoma, B-Cell - diagnosis</subject><subject>Lymphoma, B-Cell - pathology</subject><subject>Lymphoma, B-Cell - therapy</subject><subject>Lymphoma, B-Cell, Marginal Zone</subject><subject>Lymphoma, B-Cell, Marginal Zone - diagnosis</subject><subject>Lymphoma, B-Cell, Marginal Zone - pathology</subject><subject>Lymphoma, B-Cell, Marginal Zone - therapy</subject><subject>Lymphoma, Large B-Cell, Diffuse</subject><subject>Lymphoma, Large B-Cell, Diffuse - diagnosis</subject><subject>Lymphoma, Large B-Cell, Diffuse - pathology</subject><subject>Lymphoma, Large B-Cell, Diffuse - therapy</subject><subject>Male</subject><subject>MALT</subject><subject>MALT lymphoma</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>mucosa associated lymphoid tissue</subject><subject>ocular lymphoma</subject><subject>Ophthalmology</subject><subject>Patients</subject><subject>Radiation therapy</subject><subject>REAL</subject><subject>Retrospective Studies</subject><subject>Revised European-American Classification of Lymphoid Neoplasms</subject><subject>Studies</subject><subject>Surgery</subject><subject>Task forces</subject><subject>Tumors</subject><issn>0007-1161</issn><issn>1468-2079</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFksFv0zAUxi0EYt3gzA1ZQnCYSGc7jh3vgDRVG0Mq2wSjBy6WYztLOicudjrR_x6XVBvsspNtvd9773vPHwBvMJpinLOjaumnBCE2RQIVpXgGJpiyMiOIi-dgghDiGcYM74H9GJfpSRjmL8EeZoyTnIgJ-H4V2k6FDXSbbtX4TkFfw6Gx0Cm9jTgYlT6Gqoenl9-uZ9CvmqFRrms19L32zt9s4KDiLax90BbGYW02r8CLWrloX-_OA_Dj7PR6dp7NLz9_mZ3Ms6oQaMhMpU0ubM10qSiqK1GZdDEs6aU8F7VFFBtTVERQUhdUFEQYLjAhnFhhBMoPwKex7mpdddZo2w9BObkaJ5JetfL_SN828sbfSVwWHP8t8HEs0DxKOz-Zy7aPNnQSoSSGUnqHE_5h1y_4X2sbB9m1UVvnVG_9OkpWsiLpzJ8EsRBp_6xM4LtH4NKvQ5-WJjHnpSCUFCxRRyOlg48x2PpeK0ZyawOZbCC3NpCjDVLG238388Dv_j0B73eAilq5Oqhet_GB44Khkm5HzkaujYP9fR9X4VYynvNCXixmkizmF4uvP6_kWeIPR77qlk-q_ANfu9ZY</recordid><startdate>20060801</startdate><enddate>20060801</enddate><creator>Sjö, L D</creator><creator>Ralfkiaer, E</creator><creator>Juhl, B R</creator><creator>Prause, J U</creator><creator>Kivelä, T</creator><creator>Auw-Haedrich, C</creator><creator>Bacin, F</creator><creator>Carrera, M</creator><creator>Coupland, S E</creator><creator>Delbosc, B</creator><creator>Ducrey, N</creator><creator>Kantelip, B</creator><creator>Kemeny, J L</creator><creator>Meyer, P</creator><creator>Sjö, N C</creator><creator>Heegaard, S</creator><general>BMJ Publishing Group Ltd</general><general>BMJ</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><general>BMJ Group</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>1XC</scope><scope>5PM</scope></search><sort><creationdate>20060801</creationdate><title>Primary lymphoma of the lacrimal sac: an EORTC ophthalmic oncology task force study</title><author>Sjö, L D ; Ralfkiaer, E ; Juhl, B R ; Prause, J U ; Kivelä, T ; Auw-Haedrich, C ; Bacin, F ; Carrera, M ; Coupland, S E ; Delbosc, B ; Ducrey, N ; Kantelip, B ; Kemeny, J L ; Meyer, P ; Sjö, N C ; Heegaard, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b590t-dbcd39ef6c8a40fb9bd8a4d61614739fe041dd5b2942f549529d7912272e9d903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Age</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antigens, CD</topic><topic>Antigens, CD - metabolism</topic><topic>Antigens, Neoplasm</topic><topic>Antigens, Neoplasm - metabolism</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>CHOP</topic><topic>Classification</topic><topic>Clinical Science - Extended Report</topic><topic>complete remission</topic><topic>cyclophosphamide + hydroxydoxorubicine + oncovine + prednisone</topic><topic>diffuse large B cell lymphoma</topic><topic>DLBCL</topic><topic>EOPS</topic><topic>EORTC</topic><topic>European Ophthalmic Pathology Society</topic><topic>European Organization for Research and Treatment of Cancer</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Immunology</topic><topic>Lacrimal Apparatus Diseases</topic><topic>Lacrimal Apparatus Diseases - diagnosis</topic><topic>Lacrimal Apparatus Diseases - pathology</topic><topic>Lacrimal Apparatus Diseases - therapy</topic><topic>lacrimal sac</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Life Sciences</topic><topic>Lymphoma</topic><topic>Lymphoma, B-Cell</topic><topic>Lymphoma, B-Cell - diagnosis</topic><topic>Lymphoma, B-Cell - pathology</topic><topic>Lymphoma, B-Cell - therapy</topic><topic>Lymphoma, B-Cell, Marginal Zone</topic><topic>Lymphoma, B-Cell, Marginal Zone - diagnosis</topic><topic>Lymphoma, B-Cell, Marginal Zone - pathology</topic><topic>Lymphoma, B-Cell, Marginal Zone - therapy</topic><topic>Lymphoma, Large B-Cell, Diffuse</topic><topic>Lymphoma, Large B-Cell, Diffuse - diagnosis</topic><topic>Lymphoma, Large B-Cell, Diffuse - pathology</topic><topic>Lymphoma, Large B-Cell, Diffuse - therapy</topic><topic>Male</topic><topic>MALT</topic><topic>MALT lymphoma</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>mucosa associated lymphoid tissue</topic><topic>ocular lymphoma</topic><topic>Ophthalmology</topic><topic>Patients</topic><topic>Radiation therapy</topic><topic>REAL</topic><topic>Retrospective Studies</topic><topic>Revised European-American Classification of Lymphoid Neoplasms</topic><topic>Studies</topic><topic>Surgery</topic><topic>Task forces</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sjö, L D</creatorcontrib><creatorcontrib>Ralfkiaer, E</creatorcontrib><creatorcontrib>Juhl, B R</creatorcontrib><creatorcontrib>Prause, J U</creatorcontrib><creatorcontrib>Kivelä, T</creatorcontrib><creatorcontrib>Auw-Haedrich, C</creatorcontrib><creatorcontrib>Bacin, F</creatorcontrib><creatorcontrib>Carrera, M</creatorcontrib><creatorcontrib>Coupland, S E</creatorcontrib><creatorcontrib>Delbosc, B</creatorcontrib><creatorcontrib>Ducrey, N</creatorcontrib><creatorcontrib>Kantelip, B</creatorcontrib><creatorcontrib>Kemeny, J L</creatorcontrib><creatorcontrib>Meyer, P</creatorcontrib><creatorcontrib>Sjö, N C</creatorcontrib><creatorcontrib>Heegaard, S</creatorcontrib><creatorcontrib>European Organization for Research and Treatment of Cancer</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sjö, L D</au><au>Ralfkiaer, E</au><au>Juhl, B R</au><au>Prause, J U</au><au>Kivelä, T</au><au>Auw-Haedrich, C</au><au>Bacin, F</au><au>Carrera, M</au><au>Coupland, S E</au><au>Delbosc, B</au><au>Ducrey, N</au><au>Kantelip, B</au><au>Kemeny, J L</au><au>Meyer, P</au><au>Sjö, N C</au><au>Heegaard, S</au><aucorp>European Organization for Research and Treatment of Cancer</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Primary lymphoma of the lacrimal sac: an EORTC ophthalmic oncology task force study</atitle><jtitle>British journal of ophthalmology</jtitle><addtitle>Br J Ophthalmol</addtitle><date>2006-08-01</date><risdate>2006</risdate><volume>90</volume><issue>8</issue><spage>1004</spage><epage>1009</epage><pages>1004-1009</pages><issn>0007-1161</issn><eissn>1468-2079</eissn><coden>BJOPAL</coden><abstract>Aim: To define the clinical and histopathological characteristics of primary lacrimal sac lymphoma in a predominantly white population. Methods: Specimens of lacrimal sac lymphoma and follow up data were solicited from members of the Ophthalmic Oncology Task Force of the European Organization for Research and Treatment of Cancer (EORTC) and the European Ophthalmic Pathology Society (EOPS). Specimens were stained with haematoxylin and eosin and an immunohistochemical panel against leucocyte antigens was applied. Diagnosis was reached by consensus of five experienced pathologists according to the World Health Organization classification system. The histopathological findings were correlated with the clinical data. Results: Of 15 primary lacrimal sac lymphomas, five (33%) were diffuse large B cell lymphoma (DLBCL), five (33%) were extranodal marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma), three were classified as “transitional MALT lymphoma,” being in transition from MALT lymphoma to DLBCL, and two were unclassified B cell lymphomas. Nine of the patients were female, and the median age at the time of diagnosis was 71 years (range 45–95 years). The most frequent presenting symptoms were epiphora (85%), swelling in the region of the lacrimal sac (79%), and dacryocystitis (21%). All but one patient presented in stage I. Systemic spread occurred in three of nine patients (33%). The 5 year overall survival was 65%. Conclusions: DLBCL and MALT lymphoma are equally common in the lacrimal sac in contrast with the remaining periorbital and/or orbital region where MALT lymphoma predominates.</abstract><cop>BMA House, Tavistock Square, London, WC1H 9JR</cop><pub>BMJ Publishing Group Ltd</pub><pmid>16672329</pmid><doi>10.1136/bjo.2006.090589</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1161 |
| ispartof | British journal of ophthalmology, 2006-08, Vol.90 (8), p.1004-1009 |
| issn | 0007-1161 1468-2079 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1857190 |
| source | MEDLINE; BMJ Journals - NESLi2; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Age Aged Aged, 80 and over Antigens, CD Antigens, CD - metabolism Antigens, Neoplasm Antigens, Neoplasm - metabolism Biological and medical sciences Chemotherapy CHOP Classification Clinical Science - Extended Report complete remission cyclophosphamide + hydroxydoxorubicine + oncovine + prednisone diffuse large B cell lymphoma DLBCL EOPS EORTC European Ophthalmic Pathology Society European Organization for Research and Treatment of Cancer Female Hematologic and hematopoietic diseases Humans Immunology Lacrimal Apparatus Diseases Lacrimal Apparatus Diseases - diagnosis Lacrimal Apparatus Diseases - pathology Lacrimal Apparatus Diseases - therapy lacrimal sac Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Life Sciences Lymphoma Lymphoma, B-Cell Lymphoma, B-Cell - diagnosis Lymphoma, B-Cell - pathology Lymphoma, B-Cell - therapy Lymphoma, B-Cell, Marginal Zone Lymphoma, B-Cell, Marginal Zone - diagnosis Lymphoma, B-Cell, Marginal Zone - pathology Lymphoma, B-Cell, Marginal Zone - therapy Lymphoma, Large B-Cell, Diffuse Lymphoma, Large B-Cell, Diffuse - diagnosis Lymphoma, Large B-Cell, Diffuse - pathology Lymphoma, Large B-Cell, Diffuse - therapy Male MALT MALT lymphoma Medical prognosis Medical sciences Middle Aged Miscellaneous mucosa associated lymphoid tissue ocular lymphoma Ophthalmology Patients Radiation therapy REAL Retrospective Studies Revised European-American Classification of Lymphoid Neoplasms Studies Surgery Task forces Tumors |
| title | Primary lymphoma of the lacrimal sac: an EORTC ophthalmic oncology task force study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T15%3A36%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Primary%20lymphoma%20of%20the%20lacrimal%20sac:%20an%20EORTC%20ophthalmic%20oncology%20task%20force%20study&rft.jtitle=British%20journal%20of%20ophthalmology&rft.au=Sj%C3%B6,%20L%20D&rft.aucorp=European%20Organization%20for%20Research%20and%20Treatment%20of%20Cancer&rft.date=2006-08-01&rft.volume=90&rft.issue=8&rft.spage=1004&rft.epage=1009&rft.pages=1004-1009&rft.issn=0007-1161&rft.eissn=1468-2079&rft.coden=BJOPAL&rft_id=info:doi/10.1136/bjo.2006.090589&rft_dat=%3Cproquest_pubme%3E4012418311%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1778924256&rft_id=info:pmid/16672329&rfr_iscdi=true |